Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3623-3630

  Wei, Yumeng ^a   Guo, Jianmin ^b   Zheng, Xiaoli ^b   Wu, Jun ^c   Zhou, Yang ^a   Yu, Yu ^d   Ye, Yun ^a   Zhang, Liangke ^d   Zhao, Ling ^a  

^a Institute of Pharmacy   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bioavailability; In vitro release; In vivo evaluation; Nanoliposomes

Indexed keywords

BAICALIN; CARBOXYMETHYLCELLULOSE; CITRIC ACID; LIPOSOME; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; FLAVONOID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; KIDNEY; LUNG; MALE; MORPHOLOGICAL TRAIT; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; FLAVONOIDS; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84905438450     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S66312     Document Type: Article

References (44)

1. Kim AR, Kim SN, Jung IK, Kim HH, Park YH, Park WS. The inhibitory effect of Scutellaria baicalensis extract and its active compound, baicalin, on the translocation of the androgen receptor with implications for preventing androgenetic alopecia. Planta Med. 2014;80(2-3):153-158.
2. Du Z, Wang K, Tao Y, Chen L, Qiu F. Purification of baicalin and wogonoside from Scutellaria baicalensis extracts by macroporous resin adsorption chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;908:143-149.
3. Haranaka R, Hasegawa R, Nakagawa S, Sakurai A, Satomi N, Haranaka K. Antitumor activity of combination therapy with traditional Chinese medicine and OK432or MMC. J Biol Response Mod. 1988;7(1):77-90.
4. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009;35(1):57-68.
5. Yu J, Liu H, Lei J, Tan W, Hu X, Zou G. Antitumor activity of chloro-form fraction of Scutellaria barbata and its active constituents. Phytother Res. 2007;21(9):817-822.
6. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40(5):357-367.
7. Shen YC, Chiou WF, Chou YC, Chen CF. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol. 2003;465(1-2):171-181.
8. Shieh DE, Liu LT, Lin CC. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000; 20(5A):2861-2865.
9. Xing J, Chen X, Zhong D. Absorption and enterohepatic circulation of baicalin in rats. Life Sci. 2005;78(2):140-146.
10. Zhou X, Liu D, Liu H, et al. Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin. J Pharm Sci. 2010;99(7):2991-2998.
11. Yan JJ, Li AP, Li XR. [Study on techniques of preparing baicalin gelatin microspheres]. Chinese Journal of Information on Traditional Chinese Medicine. 2009;16(1):30-32. Chinese.
12. Wang YM, Yue HK, Chang M, Zhang J, Qi L. [Study on the preparation of baicalin sustained-release microcapsule]. Journal of Anhui Agricultural Sciences. 2011;39(20):12086-12088. Chinese.
13. Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769-3779.
14. Yang L, Song WZ, Zhang Y. Baicalin-cyclodextrin inclusion compound preparation. J Henan University. 2013;32(3):179-183.
15. Li JX, Han LL, Chao JB. Preparation and characterization of the inclusion complex of baicalein with -cyclodextrin: an antioxidant ability study. J Incl Phenom Macrocycl Chem. 2012;73(1-4):247-254.
16. Hao J, Wang F, Wang X, et al. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur J Pharm Sci. 2012;47(2):497-505.
17. Li B, Wen M, Li W, He M, Yang X, Li S. Preparation and characterization of baicalin-polyvinylpyrrolidone coprecipitate. Int J Pharm. 2011;408(1-2):91-96.
18. Li N, Je YJ, Yang M, Jiang XH, Ma JH. Pharmacokinetics of baicalin- phospholipid complex in rat plasma and brain tissues after intranasal and intravenous administration. Pharmazie. 2011;66(5):374-377.
19. Dicheva BM, Koning GA. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors. Expert Opin Drug Deliv. 2014;11(1):83-100.
20. Liu M, Li M, Sun S, et al. The use of antibody modified liposomes loaded with AMO-1to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials. 2014;35(11):3697-3707.
21. Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine. 2013;8:1921-1933.
22. Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomedicine. 2013;8: 951-960.
23. Wei Y, Xue Z, Ye Y, Wang P, Huang Y, Zhao L. Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. Biomed Chromatogr. 2014;28(2):204-212.
24. Wei Y, Xue Z, Ye Y, Huang Y, Zhao L. Paclitaxel targeting to lungs by way of liposomes prepared by the effervescent dispersion technique. Arch Pharm Res. 2014;37(6):728-737.
25. Wei Y, Zhao L. Passive lung-targeted drug delivery systems via intra venous administration. Pharm Dev Technol. 2014;19(2):129-136.
26. Zhao L, Wei Y, Li W, et al. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. J Drug Target. 2011;19(3):171-178.
27. Zhao L, Ye Y, Li J, Wei YM. Preparation and the in vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. J Pharm Pharmacol. 2011;63(1):80-86.
28. Zhao L, Wei YM, Zhong XD, et al. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal. 2009;49(4):989-996.
29. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012;33(28):6758-6768.
30. Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxo-rubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm. 2012;9(9):2626-2635.
31. Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bio- availability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81(2):265-272.
32. Gradauer K, Barthelmes J, Vonach C, et al. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J Control Release. 2013;172(3):872-878.
33. Wang G, Chang MQ, Yang GY, Zeng N, Ye F. Oral absorption of long circulating nano-liposomes of quercetin in mice. Herald of Medicine. 2011;30(10):1266-1269.
34. Kong XY, Du YQ, Li L, et al. Plasma miR-216a as a potential marker of pancreatic injury in a rat model of acute pancreatitis. World J Gastroenterol. 2010;16(36):4599-4604.
35. Gu YZ, Zhou W, Zhai GX. [Preparation of puerarin liposome and its oral absorption in rat]. Zhong Yao Cai. 2007;30(8):970-973. Chinese.
36. Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25(14):2843-2849.
37. Chen XQ, Yang RX. Preparation of baicalin liposome and determination of its entrapment efficiency. GuangZhou Chemical Ind Techno. 2009;37(6):138-139.
38. Liu ZF, Yang ZH, Zhang SH, Liu WL. Study on preparation and main drug content determination of baicalin liposomes. Modern Med Health. 2010;16:2411-2413.
39. Rowland RN, Woodley JF. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. Biochim Biophys Acta. 1980;620(3): 400-409.
40. Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol. 2000;52(12):1563-1568.
41. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4):286-296.
42. Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine. 2012;7:3537-3545.
43. Duchêne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm. 1997;44(1):15-23.
44. Venkatesan N, Uchino K, Amagase K, Ito Y, Shibata N, Takada K. Gastro-intestinal patch system for the delivery of erythropoietin. J Control Release. 2006;111(1-2):19-26.